Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

Abstract

Inflammatory bowel disease (IBD) is a chronic, debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor that is demonstrating therapeutic potential for the prevention or treatment of an expanding number of intestinal diseases, including short bowel syndrome (SBS), small bowel enteritis and IBD. The biological activity of GLP-2 is limited due to proteolytic inactivation by the protease dipeptidyl peptidase (DP)IV. Inhibitors of DPIV activity may represent a novel strategy to prolong the growth promoting actions of GLP-2. This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD.

• Authors: Roger Yazbeck, Gordon S Howarth, Catherine A Abbott
• Journal: Cytokine & growth factor reviews (Cytokine Growth Factor Rev) Vol. 20 Issue 2 Pg. 175-84 (Apr 2009) ISSN: 1879-0305 [Electronic] England
• PMID: 19324585 (Publication Type: Journal Article, Review)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Glucagon-Like Peptide 2
• Peptides
• teduglutide
• Dipeptidyl Peptidase 4

Topics

• Animals
• Dipeptidyl Peptidase 4 (metabolism)
• Dipeptidyl-Peptidase IV Inhibitors
• Glucagon-Like Peptide 2 (therapeutic use)
• Humans
• Inflammatory Bowel Diseases (drug therapy, physiopathology)
• Intestinal Diseases (drug therapy)
• Neoplasms (chemically induced)
• Peptides (therapeutic use)
• Short Bowel Syndrome (drug therapy)